Mersana Stock Based Compensation from 2010 to 2025
| MRSN Stock | USD 0.38 0.01 2.57% |
Stock Based Compensation | First Reported 2016-03-31 | Previous Quarter 4 M | Current Value 3.3 M | Quarterly Volatility 2.1 M |
Check Mersana Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mersana Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 8.9 M, Depreciation And Amortization of 1.1 M or Interest Expense of 4.1 M, as well as many indicators such as Price To Sales Ratio of 4.11, Dividend Yield of 0.0 or Days Sales Outstanding of 389. Mersana financial statements analysis is a perfect complement when working with Mersana Therapeutics Valuation or Volatility modules.
Mersana | Stock Based Compensation |
Latest Mersana Therapeutics' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Mersana Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Mersana Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mersana Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Mersana Stock Based Compensation Regression Statistics
| Arithmetic Mean | 6,761,570 | |
| Geometric Mean | 2,216,200 | |
| Coefficient Of Variation | 120.33 | |
| Mean Deviation | 6,834,462 | |
| Median | 3,884,000 | |
| Standard Deviation | 8,135,945 | |
| Sample Variance | 66.2T | |
| Range | 21.2M | |
| R-Value | 0.82 | |
| Mean Square Error | 22.8T | |
| R-Squared | 0.68 | |
| Significance | 0.000088 | |
| Slope | 1,407,686 | |
| Total Sum of Squares | 992.9T |
Mersana Stock Based Compensation History
Other Fundumenentals of Mersana Therapeutics
Mersana Therapeutics Stock Based Compensation component correlations
Click cells to compare fundamentals
About Mersana Therapeutics Financial Statements
Mersana Therapeutics investors utilize fundamental indicators, such as Stock Based Compensation, to predict how Mersana Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 16.5 M | 10.5 M | |
| Stock Based Compensation To Revenue | 0.41 | 0.39 |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.81 | GE | GE Aerospace | PairCorr |
| 0.77 | WM | Waste Management | PairCorr |
| 0.76 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.65 | LUCD | Lucid Diagnostics | PairCorr |
| 0.44 | MLSS | Milestone Scientific | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Mersana Therapeutics Correlation against competitors. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Revenue Per Share | Quarterly Revenue Growth 0.529 | Return On Assets | Return On Equity |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.